Generic drugmaker Orifarm considers lawsuit against scandalized Indian CRO

Contract researcher Synchron Research Service helped Danish firm Orifarm with two of its generic medicines that are now facing the possibility of removal from the European market due to their links with the Indian organization.
Orifarm, which is based on the island of Funen, Denmark, is looking into its options after learning that two of its generic medicines marketed in its home country could be removed from market | Photo: Orifarm / PR
Orifarm, which is based on the island of Funen, Denmark, is looking into its options after learning that two of its generic medicines marketed in its home country could be removed from market | Photo: Orifarm / PR
by ulrich quistgaard, translated by daniel pedersen

Orifarm, a parallel importer and seller of generic medicines, is reportedly looking into taking legal action against Indian contract research organization (CRO) Synchron Research Service following the news that the latter had conducted fraudulent drug trials

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading